Clinical trial · Interventional
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation
NCT04952168CI-TRIAL-00052574unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC, Stage III | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Almonertinib | Drug | Aumolertinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Almonertinib group
- description
- All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
- interventionNames
- Drug: Almonertinib
Primary outcomes (1)
- measure
- 2-year overall survival rate
- timeFrame
- 2 years
- description
- The 2-year overall survival rate was defined as the rate of death within 2 years
Secondary outcomes (2)
- measure
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18, male or female. 2. Patients must provide written informed consent to participate in the study. 3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th). 4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R). 5. Patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response. 6. ECOG score 0-1 7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given concurrent chemoradiotherapy 3 months after targeted therapy Exclusion Criteria: 1. Patients progress in 3 months after almonertinib treatment 2. Patient can't tolerate radiotherapy or targeted therapy 3. Pregnant or nursing women
References
Publications (0)
Data not yet available
No reference posted for this study.